Update date
30 Sep 2022
Shareable Research Card
AVEO PHARMACEUTICALS, INC. Liabilities, Current
This metric view shows AVEO PHARMACEUTICALS, INC. liabilities, current history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q3 2022
- Latest reported value
- $42,423,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 30 Sep 2022
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q3 2022.
- Latest reported value on this page: $42,423,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Liabilities, Current
Latest reported liabilities, current: $42,423,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q3 2022
SEC-backed company facts were refreshed from filings filed on 07 Nov 2022.
Benchmark Context
How Liabilities, Current compares with peers
AVEO PHARMACEUTICALS, INC. is outside the visible top 120 companies for liabilities, current in the current sample.
Compared with
Compared with 120 companies reporting liabilities, current in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Liabilities, Current is up about 90% versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Sep 2011 to 31 Mar 2026.
- Nearby companies in this sample: AMAZON COM INC and Apple Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
AVEO PHARMACEUTICALS, INC.: Liabilities, Current
Latest period: Q3 2022. Period end: 30 Sep 2022. Units: USD. Frequency: quarterly.
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Metric Snapshot
- Latest value
- $42,423,000
- Coverage range
- 31 Dec 2010 - 30 Sep 2022
- Fact rows
- 47
What This Metric Tells You
- Shows the reported level of liabilities, current over 31 Dec 2010 - 30 Sep 2022.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 47 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Liabilities, Current levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | AMAZON COM INC (amzn) | $218,005,000,000 | Instant - 31 Dec 2025 | Open AMAZON COM INC Liabilities, Current |
| 2 | Apple Inc. (aapl) | $162,367,000,000 | Instant - 27 Dec 2025 | Open Apple Inc. Liabilities, Current |
| 3 | CME GROUP INC. (cme) | $160,296,700,000 | Instant - 31 Dec 2025 | Open CME GROUP INC. Liabilities, Current |
| 4 | TOYOTA MOTOR CORP/ (tm) | $137,294,000,000 | Instant - 31 Mar 2013 | Open TOYOTA MOTOR CORP/ Liabilities, Current |
| 5 | MICROSOFT CORP (msft) | $130,005,000,000 | Instant - 31 Dec 2025 | Open MICROSOFT CORP Liabilities, Current |
| 6 | UNITEDHEALTH GROUP INC (unh) | $114,897,000,000 | Instant - 31 Dec 2025 | Open UNITEDHEALTH GROUP INC Liabilities, Current |
Metric Details
- Metric
- Liabilities, Current (LiabilitiesCurrent)
- Taxonomy
- us-gaap
- Units tracked
- USD
- Frequency coverage
- quarterly
- History range
- 31 Dec 2010 - 30 Sep 2022
- Facts on this page
- 47
- Description
- Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Liabilities, Current, Quarterly (USD)
Liabilities, Current, YoY Quarterly Change (%)
AVEO PHARMACEUTICALS, INC. Quarterly Liabilities, Current (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q3 2022 | $42,423,000 | +$20,047,000 | +90% | 30 Sep 2022 | 10-Q | 07 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $31,497,000 | +$14,022,000 | +80% | 30 Jun 2022 | 10-Q | 04 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $20,304,000 | +$531,000 | +2.7% | 31 Mar 2022 | 10-Q | 05 May 2022 | 2022 | Q1 |
| Q4 2021 | $18,731,000 | +$1,786,000 | +11% | 31 Dec 2021 | 10-Q | 07 Nov 2022 | 2022 | Q3 |
| Q3 2021 | $22,376,000 | +$5,688,000 | +34% | 30 Sep 2021 | 10-Q | 08 Nov 2021 | 2021 | Q3 |
| Q2 2021 | $17,475,000 | -$4,308,000 | -20% | 30 Jun 2021 | 10-Q | 05 Aug 2021 | 2021 | Q2 |
| Q1 2021 | $19,773,000 | -$2,266,000 | -10% | 31 Mar 2021 | 10-Q | 10 May 2021 | 2021 | Q1 |
| Q4 2020 | $16,945,000 | -$4,173,000 | -20% | 31 Dec 2020 | 10-K | 14 Mar 2022 | 2021 | FY |
| Q3 2020 | $16,688,000 | -$4,143,000 | -20% | 30 Sep 2020 | 10-Q | 09 Nov 2020 | 2020 | Q3 |
| Q2 2020 | $21,783,000 | +$2,898,000 | +15% | 30 Jun 2020 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2020 | $22,039,000 | +$3,148,000 | +17% | 31 Mar 2020 | 10-Q | 30 Apr 2020 | 2020 | Q1 |
| Q4 2019 | $21,118,000 | +$3,001,000 | +17% | 31 Dec 2019 | 10-K | 16 Mar 2021 | 2020 | FY |
| Q3 2019 | $20,831,000 | +$1,344,000 | +6.9% | 30 Sep 2019 | 10-Q | 12 Nov 2019 | 2019 | Q3 |
| Q2 2019 | $18,885,000 | +$1,718,000 | +10% | 30 Jun 2019 | 10-Q | 08 Aug 2019 | 2019 | Q2 |
| Q1 2019 | $18,891,000 | -$13,537,000 | -42% | 31 Mar 2019 | 10-Q | 09 May 2019 | 2019 | Q1 |
| Q4 2018 | $18,117,000 | -$14,007,000 | -44% | 31 Dec 2018 | 10-K | 16 Mar 2020 | 2019 | FY |
| Q3 2018 | $19,487,000 | +$1,639,000 | +9.2% | 30 Sep 2018 | 10-Q | 09 Nov 2018 | 2018 | Q3 |
| Q2 2018 | $17,167,000 | +$2,213,000 | +15% | 30 Jun 2018 | 10-Q | 07 Aug 2018 | 2018 | Q2 |
| Q1 2018 | $32,428,000 | +$18,179,000 | +128% | 31 Mar 2018 | 10-Q | 08 May 2018 | 2018 | Q1 |
| Q4 2017 | $32,124,000 | +$21,775,000 | +210% | 31 Dec 2017 | 10-K | 14 Mar 2019 | 2018 | FY |
| Q3 2017 | $17,848,000 | +$11,044,000 | +162% | 30 Sep 2017 | 10-Q | 07 Nov 2017 | 2017 | Q3 |
| Q2 2017 | $14,954,000 | +$7,990,000 | +115% | 30 Jun 2017 | 10-Q | 09 Aug 2017 | 2017 | Q2 |
| Q1 2017 | $14,249,000 | +$3,387,000 | +31% | 31 Mar 2017 | 10-Q | 04 May 2017 | 2017 | Q1 |
| Q4 2016 | $10,349,000 | -$2,049,000 | -17% | 31 Dec 2016 | 10-K | 13 Mar 2018 | 2017 | FY |
| Q3 2016 | $6,804,000 | -$3,613,000 | -35% | 30 Sep 2016 | 10-Q | 04 Nov 2016 | 2016 | Q3 |
| Q2 2016 | $6,964,000 | -$7,523,000 | -52% | 30 Jun 2016 | 10-Q | 04 Aug 2016 | 2016 | Q2 |
| Q1 2016 | $10,862,000 | -$15,693,000 | -59% | 31 Mar 2016 | 10-Q | 10 May 2016 | 2016 | Q1 |
| Q4 2015 | $12,398,000 | -$27,957,000 | -69% | 31 Dec 2015 | 10-K | 22 Mar 2017 | 2016 | FY |
| Q3 2015 | $10,417,000 | -$28,464,000 | -73% | 30 Sep 2015 | 10-Q | 09 Nov 2015 | 2015 | Q3 |
| Q2 2015 | $14,487,000 | -$18,510,000 | -56% | 30 Jun 2015 | 10-Q | 10 Aug 2015 | 2015 | Q2 |
| Q1 2015 | $26,555,000 | -$6,089,000 | -19% | 31 Mar 2015 | 10-Q | 07 May 2015 | 2015 | Q1 |
| Q4 2014 | $40,355,000 | +$8,947,000 | +28% | 31 Dec 2014 | 10-K | 15 Mar 2016 | 2015 | FY |
| Q3 2014 | $38,881,000 | +$7,151,000 | +23% | 30 Sep 2014 | 10-Q | 05 Nov 2014 | 2014 | Q3 |
| Q2 2014 | $32,997,000 | -$1,691,000 | -4.9% | 30 Jun 2014 | 10-Q | 11 Aug 2014 | 2014 | Q2 |
| Q1 2014 | $32,644,000 | -$5,102,000 | -14% | 31 Mar 2014 | 10-Q | 07 May 2014 | 2014 | Q1 |
| Q4 2013 | $31,408,000 | -$7,722,000 | -20% | 31 Dec 2013 | 10-K | 06 Mar 2015 | 2014 | FY |
| Q3 2013 | $31,730,000 | -$2,936,000 | -8.5% | 30 Sep 2013 | 10-Q | 07 Nov 2013 | 2013 | Q3 |
| Q2 2013 | $34,688,000 | +$5,557,000 | +19% | 30 Jun 2013 | 10-Q | 08 Aug 2013 | 2013 | Q2 |
| Q1 2013 | $37,746,000 | +$12,697,000 | +51% | 31 Mar 2013 | 10-Q | 10 May 2013 | 2013 | Q1 |
| Q4 2012 | $39,130,000 | +$4,521,000 | +13% | 31 Dec 2012 | 10-K | 13 Mar 2014 | 2013 | FY |
| Q3 2012 | $34,666,000 | +$2,746,000 | +8.6% | 30 Sep 2012 | 10-Q | 08 Nov 2012 | 2012 | Q3 |
| Q2 2012 | $29,131,000 | -$3,870,000 | -12% | 30 Jun 2012 | 10-Q | 07 Aug 2012 | 2012 | Q2 |
| Q1 2012 | $25,049,000 | 31 Mar 2012 | 10-Q | 09 May 2012 | 2012 | Q1 | ||
| Q4 2011 | $34,609,000 | -$7,484,000 | -18% | 31 Dec 2011 | 10-K | 11 Mar 2013 | 2012 | FY |
| Q3 2011 | $31,920,000 | 30 Sep 2011 | 10-Q | 08 Nov 2011 | 2011 | Q3 | ||
| Q2 2011 | $33,001,000 | 30 Jun 2011 | 10-Q | 09 Aug 2011 | 2011 | Q2 | ||
| Q4 2010 | $42,093,000 | 31 Dec 2010 | 10-K | 30 Mar 2012 | 2011 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.